The latest data on the investigational drug regorafenib (BAY 73-4506)from the Phase III CORRECT trial(Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) were presented at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.
Regorafenib (BAY 73-4506) is an an investigational oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. The drug is at this time not approved by the FDA, EMA or other health authorities.
Statistically significant improvement
The CORRECT study was a multicenter, randomized, double-blind, placebo-controlled Phase III study enrolled 760 patients with mCRC whose disease had progressed during or within 3 months following last administration of approved standard therapies, which included fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab or panitumumab.
Patients who had withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease were also allowed into the study.
Patients were randomized to receive either regorafenib plus best supportive care (BSC) or placebo plus BSC. Treatment cycles consisted of 160 mg of regorafenib (or matching placebo) once daily for three weeks on / one week off plus BSC.
The study results showed that the CORRECT study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 months for the placebo group) in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies.[I] This late-breaking abstract, with these updated data, were be presented by Axel Grothey, MD, Professor of Oncology, Mayo Clinic and co-principal investigator of the CORRECT study, in an oral abstract session (ASCO-GI, LBA No. 385, January 21, 2012 from 2:30 p.m. ? 4:00 p.m. PT, Level 3 Ballroom, Moscone Center West).
Additionally, findings from the secondary endpoints of the CORRECT study showed statistically significant improvement in progression-free survival (PFS) (HR=0.49, p<0.000001, median PFS: 1.9 months vs. 1.7 months) and an improvement in disease control rate (44.8% vs. 15.3%) in patients treated with regorafenib compared to those treated with placebo. The difference in objective response rate between the two arms (1.0% vs. 0.4%) did not reach statistical significance.
The most common drug-related, treatment-emergent adverse events included fatigue (47.4% vs. 28.1%), hand-foot skin reaction (46.6% vs. 7.5%), diarrhea (33.8% vs. 8.3%), anorexia (30.4% vs. 15.4%), hypertension (27.8% vs. 5.9%), oral mucositis (27.2% vs. 3.6%) and rash/desquamation (26.0% vs. 4.0%) for patients receiving regorafenib as compared to placebo.
Data Monitoring Committee
Per the recommendation from an independent Data Monitoring Committee, the CORRECT study was unblinded in late 2011 following a pre-planned interim analysis that determined that the regorafenib arm showed significant improvement in overall survival; patients on the placebo arm were unblinded and offered treatment with regorafenib. Based on the results of the trial, Bayer plans to submit regorafenib for marketing authorization in mCRC in 2012.
Colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or rectum. The majority of cancers occurring in the colon and rectum are adenocarcinomas, which account for more than 90 percent of all large bowel tumors.  CRC is the third most commonly diagnosed cancer and the third leading cause of cancer death in the United States, in both men and women.  It is estimated that more than 140,000 people will be diagnosed with CRC in 2011, and nearly 50,000 people will die from the disease. Approximately 50% of colon cancer patients will be diagnosed with metastases (most commonly to the liver) either at the time of diagnosis or due to recurrent disease.
 A. Grothey, et al. Results of a randomized Phase 3 trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with mCRC who have progressed after standard therapies [January 17, 2012 ASCO-GI Presscast Presentation]. 2012 Gastrointestinal Cancers Symposium; January 19-21, 2012. San Francisco, CA.
 American Cancer Society. Colorectal Cancer Guide. Last accessed on October 14, 2011.
 American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. Last accessed on October 24, 2011.
 National Cancer Institute. Colon and Rectal Cancer. Last accessed on October 24, 2011.
 National Cancer Institute. Stage IV and Recurrent Colon Cancer. Last accessed on October 24, 2011.
 S. Wilhelm, et al. Regorafenib (Bay 73-4506): A New Oral Multikinase Inhibitor of Angiogenic, Stromal, and Oncogenic Receptor Tyrosine Kinases with Potent Preclinical Antitumor Activity. Online International Journal of Cancer. December 17, 2010.